Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib

Abstract Background Sorafenib represents the standard of care targeted therapy for patients with advanced hepatocellular carcinoma (HCC). However, biomolecules that predict a patient's response to sorafenib treatment for HCC remain largely unknown. Thus, this study was designed to investigate w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of surgical oncology 2013-09, Vol.39 (9), p.974-980
Hauptverfasser:	Chen, D, Zhao, P, Li, S.-Q, Xiao, W.-K, Yin, X.-Y, Peng, B.-G, Liang, L.-J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - mortality Extracellular Signal-Regulated MAP Kinases - metabolism Female Hematology, Oncology and Palliative Medicine Hepatocellular carcinoma Humans Immunohistochemistry Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - mortality Male Middle Aged Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Phosphorylated ERK Phosphorylation Prognosis Prognostic markers PTEN Phosphohydrolase - metabolism Ribosomal Protein S6 Kinases, 70-kDa - metabolism Sorafenib Surgery Treatment Outcome Vascular Endothelial Growth Factor Receptor-2 - metabolism Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!